GlaxoSmtihKline will pay $90 million to North Carolina and 37 other states to settle allegations that it unlawfully promoted its diabetes drug Avandia, state Attorney General Roy Cooper's office announced Thursday.
North Carolina will receive $2,673,740 as part of the settlement. The State Health Plan also recovered $400,000.
Under the settlement, GSK agreed to reform how it markets and promotes diabetes drugs. The company also must post summaries of all observational studies and clinical trials of diabetes products within eight months of the primary completion date.
GSK employs about 4,000 people in Research Triangle Park, which is the London-based company's North American headquarters.
GSK has about about 600 workers in Zebulon, where it makes respiratory treatments Advair and Ventolin, as well as HIV medicines Combivir, Retrovir, Trizivir and Ziagen.
Cooper's office recovered $31.8 million from GSK earlier this year over allegations that the company made false representations about the safety and efficacy of Avandia and other drugs.